Non-Antibacterial Effects of Fusidic Acid

Petrunin D.D.; Khismatullina Z.R.

doi:https://doi.org/10.17116/klinderma202423061647

Abstract:

The review systematizes and analyzes the literature data about the pharmacodynamic effects alongside the established antibacterial properties of the antibiotic substance — fusidic acid from the fusidane class. According to several sources, the substance is characterized with its anti-inflammatory, immunosuppressive, anticancer, and antiviral activities. It has been proven that fusidic acid can inhibit lymphocyte activation and the production of pro-inflammatory cytokines in lymphocytes, mononuclear cells, and leukocyte chemotaxis. It inhibits the activation and proliferation of T-lymphocytes in response to phytohemagglutinin and the development of septic shock in response to S. aureus enterotoxin and LPS. The cytoprotective action of fusidic acid on pancreatic islet cells is demonstrated in a model of insulin and glial cells exposed to a cytotoxic substance. When applied externally, its anti-inflammatory effect is comparable to that of low- and moderately-active glucocorticosteroids. The efficacy of fusidic acid in reducing inflammation-induced edema of epidermal proliferation and decreasing the synthesis of critical pro-inflammatory cytokines is comparable to that of dexamethasone at equivalent concentrations. The immunomodulatory and anti-inflammatory properties of this antibiotic substance are clinically significant, enhancing its antibacterial effect, facilitating quicker relief of inflammation, resolution of inflammatory infiltrates, improvement of patient’s quality of life by expediting the removal of unpleasant sensations associated with inflammation and mitigating the repercussions of the inflammatory process.

Keywords:

fusidic acid

non-antibacterial effects

anti-inflammatory effect

Authors:

Petrunin D.D.

LEO Pharmaceutical Products LLC

ORCID: 0000-0002-6309-7044

Khismatullina Z.R.

Bashkir State Medical University

ORCID: 0000-0001-8674-2803

Received:

26.09.2024

Accepted:

15.10.2024

Close metadata

References:

Reijnders TD, Saris A, Schultz MJ, van der Poll T. Immunomodulation by macrolides: therapeutic potential for critical care. Lancet Respir Med. 2020;8:619-630. https://doi.org/10.1016/S2213-2600(20)30080-1
Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics — part 1: biological mechanisms. Respiration. 2011;81:67-74. https://doi.org/10.1159/000320319
Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics — part 2: Advantages and Disadvantages of Long-Term, Low-Dose Macrolide Therapy. Respiration. 2011; 81:75-87. https://doi.org/10.1159/000320320
Alzolibani AA, Zedan K. Macrolides in chronic inflammatory skin disorders. Mediators Inflamm. 2012;2012:159354. https://doi.org/10.1155/2012/159354
Monk E, Shalita A, Siegel DM. Clinical applications of non-antimicrobial tetracyclines in dermatology. Pharmacol Res. 2011 Feb;63(2):130-145. https://doi.org/10.1016/j.phrs.2010.10.007
Perret LJ, Tait CP. Non-antibiotic properties of tetracyclines and their clinical application in dermatology. Australas J Dermatol. 2014 May;55(2): 111-118. https://doi.org/10.1111/ajd.12075
Wilkinson JD. Fusidic acid in dermatology. Br J Dermatol. 1998;139(53):37-40. https://doi.org/10.1046/j.1365-2133.1998.1390s3037.x
Godtfredsen W, Roholt K, Tybring L. Fucidin A new orally active antibiotic. Lancet. 1962;1(7236):928-931. https://doi.org/10.1016/s0140-6736(62)91968-2
Petrunin DD. Microbiome of human skin — its immunohomeostatic role and the role in pathogenesis of skin diseases. Russian Journal of Allergy. 2018;15(1):63-81. (In Russ.). https://doi.org/10.36691/RJA.151
Barber M, Waterworth PM. Antibacterial activity in vitro of Fucidin. Lancet. 1962 May 05;1(7236):931-932. https://doi.org/10.1016/s0140-6736(62)91969-4
Skov R, Frimodt-Møller N, Espersen F. Correlation of MIC methods and tentative interpretive criteria for disk diffusion susceptibility testing using NCCLS methodology for fusidic acid. Diagn Microbiol Infect Dis. 2001 Jul;40(3):111-116. https://doi.org/10.1016/s0732-8893(01)00262-0
Schofer H, Simonsen L. Fusidic acid in dermatology: an updated review. Eur J Dermatol. 2010;20(1):6-15. https://doi.org/10.1684/ejd.2010.0833
Banck G, Forsgren A. Antibiotics and suppression of lymphocyte function in vitro. Antimicrob Agents Chemother. 1979 Nov;16(5):554-560. https://doi.org/10.1128/AAC.16.5.554
Forsgren A, Schmeling D. Effect of antibiotics on chemotaxis of human leukocytes. Antimicrob Agents Chemother. 1977;11:580-584. https://doi.org/10.1128/AAC.11.4.580
Bellahsène A, Forsgren A. Effect of fusidic acid on the immune response in mice. Infect Immun. 1980 Sep;29(3):873-878. https://doi.org/10.1128/iai.29.3.873-878.1980
Bendtzen K, Diamant M, Faber V. Fusidic acid, an immunosuppressive drug with functions similar to cyclosporin A. Cytokine. 1990 Nov;2(6):423-429. https://doi.org/10.1016/1043-4666(90)90051-t
Chen YL, Le Vraux V, Giroud JP, Chauvelot-Moachon L. Anti-tumor necrosis factor properties of non-peptide drugs in acute-phase responses. Eur J Pharmacol. 1994 Dec 27;271(2-3):319-327. https://doi.org/10.1016/0014-2999(94)90789-7
Nicoletti F, Zaccone P, Di Marco R, Magro G, Grasso S, Morrone S, Santoni A, Tempera G, Meroni PL, Bendtzen K. Effects of sodium fusidate in animal models of insulin-dependent diabetes mellitus and septic shock. Immunology. 1995 Aug;85(4):645-650.
Genovese F, Mancuso G, Cuzzola M, Cusumano V, Nicoletti F, Bendtzen K, Teti G. Improved survival and antagonistic effect of sodium fusidate on tumor necrosis factor alpha in a neonatal mouse model of endotoxin shock. Antimicrob Agents Chemother. 1996 Jul;40(7):1733-1735. https://doi.org/10.1128/AAC.40.7.1733
Nicoletti F, Meroni PL, Lunetta M, Vigo R, Palermo T, Papalia D, Barcellini W, Di Mauro M, Caruso-Nicoletti M, Mughini L, et al. Sodium fusidate and increased remission rate of insulin-dependent diabetes mellitus. Lancet. 1991 May 25;337(8752):1292. https://doi.org/10.1016/0140-6736(91)92964-4
Bendtzen K, Diamant M, Horn T, Pedersen C, Buschard K. Effect of fusidic acid on interleukin-1 (IL-1)- and IL-6-induced pancreatic beta-cell functions in rats. J Endocrinol. 1992 Mar;132(3):345-352. https://doi.org/10.1677/joe.0.1320345
Buschard K, Pedersen C, Hansen SV, Hageman I, Aaen K, Bendtzen K. Anti-diabetogenic effect of fusidic acid in diabetes prone BB rats. Autoimmunity. 1992;14(2):101-104. https://doi.org/10.3109/08916939209083127
Nicoletti F, Di Marco R, Morrone S, Zaccone P, Lembo D, Grasso S, Santoni A, Meroni PL, Bendtzen K. Reduction of spontaneous autoimmune diabetes in diabetes-prone BB rats with the novel immunosuppressant fusidic acid. Effect on T-cell proliferation and production of interferon-gamma. Immunology. 1994 Feb;81(2):317-321.
Park E, Kim DK, Kim CS, Kim JS, Kim S, Chun HS. Protective effects of fusidic acid against sodium nitroprusside-induced apoptosis in C6 glial cells. Neuroreport. 2019 Dec 10;30(17):1222-1229. https://doi.org/10.1097/WNR.0000000000001354
Rubisz-Brzezińska J, Zebracka T, Mozdzanowski J, Mozdzanowska K. Therapieversuch mit Fucidin bei systemischer Sklerodermie Therapeutic trial with fucidin in systemic scleroderma. Z Hautkr. 1984 Dec 01;59(23):1611-1619. (In German).
Rubisz-Brzezińska J, Zebracka T, Mozdzanowska K, Mozdzanowski J. Leczenie twardziny układowej fucydyna z uwzglednieniem oceny klinicznej i badania wolnych aminokwasów surowicy. Treatment of systemic scleroderma with fucidin in relation to clinical evaluation and analysis of free amino acids in the serum. Przegl Dermatol. 1986 Jul-Aug;73(4):305-311. (In Polish).
Langholz E, Brynskov J, Freund LG, Bendtzen K. Fusidic acid for Behçet’s colitis: a novel approach to T-cell specific immunosuppressive therapy. Dan Med Bull. 1991 Jun;38(3):284.
Langholz E, Brynskov J, Bendtzen K, Vilien M, Binder V. Treatment of Crohn’s disease with fusidic acid: an antibiotic with immunosuppressive properties similar to cyclosporin. Aliment Pharmacol Ther. 1992 Aug;6(4): 495-502. https://doi.org/10.1111/j.1365-2036.1992.tb00563.x
Langholz E and the Danish Fucidin Study Group. A placebo-controlled double-blind randomised 12 week trial of Fucidin therapy in active Crohn’s disease. American Gastroenterological Association, 1995 (meeting abstract).
Wu PP, He H, Hong WD, Wu TR, Huang GY, Zhong YY, Tu BR, Gao M, Zhou J, Zhao SQ, Li DL, Xu XT, Sheng ZJ, Ward SA, O’Neill PM, Zhang K. The biological evaluation of fusidic acid and its hydrogenation derivative as antimicrobial and anti-inflammatory agents. Infect Drug Resist. 2018 Oct 24;11:1945-1957. https://doi.org/10.2147/IDR.S176390
Kilic FS, Erol K, Batu O, Yildirim E, Usluer G. The effects of fusidic acid on the inflammatory response in rats. Pharmacol Res. 2002 Apr;45(4):265-267. https://doi.org/10.1006/phrs.2001.0946
Wei M, Li L, Zhang XF, Li M, Wang B, Yan Y. Fusidic acid cream comparatively minimizes signs of inflammation and postinflammatory hyperpigmentation after ablative fractional CO2 laser resurfacing in Chinese patients: A randomized controlled trial. J Cosmet Dermatol. 2021 Jun;20(6):1692-1699. https://doi.org/10.1111/jocd.13735
Kim JY, Jegal BS, Koh AR, Park KS, Kim JB, Bae J. Growth inhibition by fusidic acid in cervical, thyroid, and breast carcinoma cell lines. Obstet Gynecol Sci. 2023 Mar;66(2):100-106. https://doi.org/10.5468/ogs.22267
Ni J, Guo M, Cao Y, Lei L, Liu K, Wang B, Lu F, Zhai R, Gao X, Yan C, Wang H, Bi Y. Discovery, synthesis of novel fusidic acid derivatives possessed amino-terminal groups at the 3-hydroxyl position with anticancer activity. Eur J Med Chem. 2019 Jan 15;162:122-131. https://doi.org/10.1016/j.ejmech.2018.10.059
Hetmann M, Langner C, Durmaz V, Cespugli M, Köchl K, Krassnigg A, Blaschitz K, Groiss S, Loibner M, Ruau D, Zatloukal K, Gruber K, Steinkellner G, Gruber CC. Identification and validation of fusidic acid and flufenamic acid as inhibitors of SARS-CoV-2 replication using DrugSolver CavitomiX. Sci Rep. 2023 Jul 21;13(1):11783. https://doi.org/10.1038/s41598-023-39071-z
Famularo G, De Simone C, Tzantzoglou S, Trinchieri V, Moretti S, Tonietti G. In vivo and in vitro efficacy of fusidic acid in HIV infection. Ann N Y Acad Sci. 1993 Jun 23;685:341-343. https://doi.org/10.1111/j.1749-6632.1993.tb35885.x
Faber V, Dalgleish AG, Newell A, Malkovsky M. Inhibition of HIV replication in vitro by fusidic acid. Lancet. 1987 Oct 10;2(8563):827-828. https://doi.org/10.1016/s0140-6736(87)91016-6